ADX40-Lymphoma

Preclinical efficacy has been demonstrated when ADX40 was conjugated to a lymphoma-specific antigen. These data raise the possibility that ADX40 may have utility as both carrier and adjuvant in idiotype vaccines for this disease. 

Products